Patient info Open main menu

Flixotide Evohaler 250 micrograms – Summary of Product Characteristics (SmPC) for healthcare professionals

Text from the MHRA, as of · About this document

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, other medicines, pregnancy and breast-feeding.

Medicine strength:
250 micrograms
Contains active substance:

Summary of Product Characteristics (SmPC) - Flixotide Evohaler 250 micrograms

1. Trade Name of the Medicinal Product

Not applicable

2. Qualitative and Quantitative Composition

Not applicable

3. Pharmaceutical Form

Not applicable

Clinical Particulars

4.1. Therapeutic Indications

Not applicable

4.2. Posology and Method of Administration

Not applicable

4.3. Contra-indications

Not applicable

4.4. Special Warnings and Precautions for Use

Not applicable

4.5. Interactions with other Medicaments and other forms of Interaction

Not applicable

4.6. Pregnancy and Lactation

Not applicable

4.7. Effects on Ability to Drive and Use Machines

Not applicable

4.8. Undesirable Effects

Not applicable

4.9. Overdose

Not applicable

Pharmacological Properties

5.1. Pharmacodynamic Properties

Not applicable

5.2. Pharmacokinetic Properties

Not applicable

5.3. Preclinical Safety Data

Not applicable

Pharmaceutical Particulars

6.1. List of Excipients

Not applicable

6.2. Incompatibilities

Not applicable

6.3. Shelf Life

Not applicable

6.4. Special Precautions for Storage

Not applicable

6.5. Nature and Contents of Container

Not applicable

6.6. Instruction for Use/Handling

Not applicable

Administrative Data

7. Marketing Authorisation Holder

Not applicable

8. Marketing Authorisation Number

Not applicable

9. Date of First Authorisation/Renewal of Authorisation

Not applicable

10. Date of (Partial) Revision of the Text

Not applicable

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLPI 15361/0373

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Flixotide Evohaler 250 micrograms

Active substance Fluticasone
Strength 250 micrograms
Marketing authorisation PLPI 15361/0373, PLPI 19488/1964

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.